Multiplexed Protease Activity Assay for Low-Volume Clinical Samples Using Droplet-Based Microfluidics and Its Application to Endometriosis

Journal of the American Chemical Society (Impact Factor: 12.11). 11/2012; 135(5). DOI: 10.1021/ja307866z
Source: PubMed


As principal degrading enzymes of the extracellular matrix, metalloproteinases contribute to various pathologies and represent a family of promising drug targets and biomarker candidates. However, multiple proteases and endogenous inhibitors interact to govern metalloproteinase activity, often leading to highly context-dependent protease function that unfortunately has impeded associated clinical utility. We present a method for rapidly assessing the activity of multiple specific proteases in small volumes (<20µl) of complex biological fluids such as clinical samples which are only available in very limited amounts. We have developed a droplet-based microfluidic platform that injects the sample into thousands of picoliter-scale droplets from a barcoded droplet library containing mixtures of unique moderately selective FRET-based protease substrates and specific inhibitors and monitors hundreds of the reactions thus initiated simultaneously by tracking these droplets. Specific protease activities in the sample are then inferred from the reaction rates using a deconvolution technique, Proteolytic Activity Matrix Analysis (PrAMA). Using a nine-member droplet library with three inhibitors and four FRET substrates, we apply the method to the peritoneal fluid of subjects with and without the invasive disease of endometriosis. Results show clear and physiologically relevant differences with disease; in particular, decreased MMP-2 and ADAM-9 activities.

Download full-text


Available from: Chia-Hung Chen, Nov 05, 2014
  • Source
    • "The integration of a target-molecule concentrator and the droplet system significantly reduced the assay time and required sample volume. The same group reported a similar multiplexed protease-activity assay to identify the activity of many specific proteases in small volumes (<20 µL) of complex biological fluids, such as clinical samples[41]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Genetic and functional heterogeneity of tumor cells represents major obstacles to cancer research, detection and effective treatment. In order to develop new therapeutic approaches in an era of personalized medicine, it is important to understand the functional characteristics of DNA, RNA, and proteins at the single-molecule level in individual cancer cells. Droplet microfluidics has emerged as a new tool that offers advantages in analyzing single molecules and single cells for high-throughput analysis with exceptional sensitivity. In this review, we highlight some recent reports that employed droplet microfluidics for cancer research, diagnostics, and therapeutics, and offer a view into future applications.
    TrAC Trends in Analytical Chemistry 06/2014; 58. DOI:10.1016/j.trac.2014.03.006 · 6.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Enzyme kinetics and inhibition is important for a wide range of disciplines including pharmacology, medicine and industrial bioprocess technology. We present a novel microdroplet-based device for extensive characterization of the reaction kinetics of enzyme substrate inhibitor systems in a single experiment utilizing an integrated droplet picoinjector for bioanalysis. This device enables the scanning of multiple fluorescently-barcoded inhibitor concentrations and substrate conditions in a single, highly time-resolved experiment yielding the Michaelis constant (Km), the turnover number (kcat) and the enzyme inhibitor dissociation constants (ki, ki'). Using this device we determine Km and kcat for β-galactosidase and the fluorogenic substrate Resorufin β-d-galactopyranoside (RBG) to be 442 μM and 1070 s-1, respectively. Furthermore, we examine the inhibitory effects of isopropyl-β-d-thiogalactopyranoside (IPTG) on β-galactosidase. This system has a number of potential applications, for example it could be used to screen inhibitors to pharmaceutically relevant enzymes and to characterize engineered enzyme variants for biofuels production, in both cases acquiring detailed information about the enzyme catalysis and enzyme inhibitor interaction at high throughput and low cost.
    Lab on a Chip 03/2013; 13(9). DOI:10.1039/c3lc41398e · 6.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the postgenome era, biology and medicine are rapidly evolving towards quantitative and systems studies of complex biological systems. Emerging breakthroughs in microfluidic technologies and innovative applications are transforming systems biology by offering new capabilities to address the challenges in many areas, such as single-cell genomics, gene regulation networks, and pathology. In this review, we focus on recent progress in microfluidic technology from the perspective of its applications to promoting quantitative and systems biomolecular analysis in biology and medicine.
    Analytical and Bioanalytical Chemistry 04/2013; 405(17). DOI:10.1007/s00216-013-6930-1 · 3.44 Impact Factor
Show more